Composition: Erutic-25: Each film coated tablet contains Eplerenone BP 25 mg.
Erutic-50: Each film coated tablet contains Eplerenone BP 50 mg.
Indications: It is indicated for improving survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction, and the treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
Dosage and Administrations: Heart failure with reduced ejection fraction (HFrEF) post an acute myocardial infarction: Initiate treatment with 25 mg once daily. Titrate to maximum of 50 mg once daily within 4 weeks, as tolerated. Dose adjustments may be required based on potassium levels. Hypertension: 50 mg once daily, alone or combined with other antihypertensive agents. For inadequate response, increase to 50 mg twice daily. Or, as directed by the registered physician.
Use in Pregnancy and Lactation: Pregnancy : There are no adequate and well-controlled studies in pregnant women. Eplerenone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers : The concentration of Eplerenone in human breast milk after oral administration is unknown, because many drugs are excreted in human milk and because of the unknown potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Packing: Erutic-25: Each box contains 28's tablets in blister pack.
Erutic-50: Each box contains 98's tablets in blister pack.
© Copyright Drug International Ltd. 2023 Designed and Developed by ATI Limited.